Literature DB >> 12859672

Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

Cathy Andorfer1, Yvonne Kress, Marisol Espinoza, Rohan de Silva, Kerry L Tucker, Yves-Alain Barde, Karen Duff, Peter Davies.   

Abstract

Neurofibrillary tangles are composed of insoluble aggregates of the microtubule-associated protein tau. In Alzheimer's disease the accumulation of neurofibrillary tangles occurs in the absence of tau mutations. Here we present mice that develop pathology from non-mutant human tau, in the absence of other exogenous factors, including beta-amyloid. The pathology in these mice is Alzheimer-like, with hyperphosphorylated tau accumulating as aggregated paired helical filaments. This pathologic tau accumulates in the cell bodies and dendrites of neurons in a spatiotemporally relevant distribution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859672     DOI: 10.1046/j.1471-4159.2003.01879.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  303 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

3.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 4.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

5.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

6.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

7.  Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Authors:  Julia Gerson; Diana L Castillo-Carranza; Urmi Sengupta; Riddhi Bodani; Donald S Prough; Douglas S DeWitt; Bridget E Hawkins; Rakez Kayed
Journal:  J Neurotrauma       Date:  2016-04-22       Impact factor: 5.269

8.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Authors:  Tara L Spires; Jennifer D Orne; Karen SantaCruz; Rose Pitstick; George A Carlson; Karen H Ashe; Bradley T Hyman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 9.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 10.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.